“United Laboratories USLEN” insulin glargin gained experts’ recognition and recommendation

By   /  May 14, 2017  /  Comments Off on “United Laboratories USLEN” insulin glargin gained experts’ recognition and recommendation

    Print       Email

Source: Media Outreach

Headline: “United Laboratories USLEN” insulin glargin gained experts’ recognition and recommendation

HONG
KONG, CHINA – Media OutReach – 14 May 2017 – The United Laboratories International
Holdings Limited (“TUL”, the “Company” or the “Group”;
HKSE: 3933), participated the “Basal Insulin Clinical Application
Summit” in Zhuhai, the PRC, hosted by Chinese Journal of Diabetes
Mellitus, together with a launching ceremony for the nationwide roll
out of”United Laboratories USLEN”. Hundreds of well-known experts
and clinical doctors in the field of diabetes attended the summit
while guest speakers are invited for themed presentation and academic
exchange regarding the usage of basal insulin in China. This summit
marked the official roll out of “United Laboratories USLEN”
insulin glargin and a new era of TUL’s development, endeavouring to
improve the treatment of diabetes in China.

TUL
has been committed to research and development of medication for
diabetes treatment. In early 2017, the Group gained the production
approval for “United Laboratories USLEN” insulin glargin
injection for the specification of refilled pen-type as well as the
specification of disposable pen-type from China State Food and Drug
Administration (“SFDA”). “United Laboratories USLEN”injection
is developed and produced with international advanced purification
technology and production facilities. The quality of product is in
full compliance with the US Pharmacopoeia standards, while its
efficacy and safety are comparable with the original research
product. Regarding the usage, the fillings and injection pen are
connected in the same injection device for the disposable pen-type,
which is convenient to carry and use; while the refilled pen-type
should be combined with the “United Lab Pen” (insulin injection
pen) which can be reused. Patients can choose from insulin products
with different specifications depends on their circumstances.

Currently,
“United Laboratories USLEN” has won the tender through bidding in
Fujian, Chongqing, Heilongjiang and Henan provinces and the Group
will actively continue to participate in the bidding in other
provinces. The product will start to be manufactured and be rolled
out this month. It is expected insulin glargin will be the lead of
insulin analogues product series and accelerate the Group’s
development, boosting its sales and profitability.

Mr.
Tsoi Hoi Shan, Chairman of TUL
,
said, “Insulin product series will continue to be the Group’s key
strategic specification.We are delighted that the launch of insulin
glargine gained extensive recognition in the market. In the future,
the Group will keep on investing inresearch and development
capability enhancement anddevelop more new products, aiming to
provide the best medical treatment to patients, hence bringing better
returnstothe Group and its shareholders.”

Company
Information

Listed
on the Stock Exchange of Hong Kong in June 2007, TUL is one of the
leading pharmaceutical companies in China, principally engaged in the
manufacturing and selling of medicines, and the bulk and intermediate
products used to produce finished goods. Up to now, the Group has a
total of 188 products qualified to produce in the PRC and/or Hong
Kong based on the Drug Registration Approvals in the PRC and
Certificates of Drug or Product Registration in Hong Kong, 84 were in
production. The Group has 49 finished products listed in National
Insurance Catalogue and 26 are in the list of the National Essential
Drug List. The Group is currently a component of the Hang Seng
Composite Index Series.

Published and distributed with permission of Media-Outreach.com.

    Print       Email